Unpublished And Under Review? US FDA’s CBD Policy Draft Guidance Still Has Industry Talking

Supplements containing hemp-derived cannabidiols aren’t typical products subject to FDA’s regulatory oversight, and the document stating its thinking on enforcement in the market submitted to the Office of Management and Budget isn’t a typical draft guidance.

CBD Cannabidiol Marijuana Cannabis Time Clocks Deadline 3d Illustration

An unpublished draft guidance the US Food and Drug Administration submits for White House review and clearance typically sparks little to no speculation by stakeholders on the extent and the details of the documents’ content.

Non-drug products containing hemp-derived cannabidiols aren’t typical products subject to the FDA’s regulatory oversight, though, and the document stating its...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Regulation

More from Policy & Regulation